0.0250 (0.00%)View full PRR report with
Page 1 of 1
  1. 1.8k

    Great news. Cheap down here.

    SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (Prima, the Company)

    announces that the US patent number 8,771,701 titled Compositions for immunotherapy and

    uses thereof, which protects the Companys CVac technology, has been granted by the

    United States Patent and Trademark Office (USPTO).

    Prima has also received a patent term adjustment of 1,409 days for US 8,771,701, extending the

    patent expiry date for the US market to August 2022.

    Chief Executive Officer of Prima, Mr Marc Voigt said: The grant of this key US patent with a

    patent term adjustment of almost four years is an important value proposition for Prima. The

    patent term can potentially be further extended by up to five years if CVac receives market

    approval before it expires, which would provide the Company with essential protection over its

    commercial development well into the future. :lol: :cool:

    1 like
  2. 47

    I was beggining to think I was the only one following this stock. It is starting to look cheap, either as a growth stock or a takeover with a juicy patent on a fast track drug. :lol:

Your browser is too old for TopStocks and not secure. Please update your browser